[HTML][HTML] Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence

E Urias, SV Ramani - Journal of International Business Policy, 2020 - ncbi.nlm.nih.gov
Abstract While Trade-Related Aspects of Intellectual Property Rights (TRIPS) was expected
to hike up prices of patented medicines, there was no consensus on its likely final impact on …

The breakthrough of biosimilars: a twist in the narrative of biological therapy

ER Kabir, SS Moreino, MK Sharif Siam - Biomolecules, 2019 - mdpi.com
The coming wave of patent expiries of first generation commercialized biotherapeutical
drugs has seen the global market open its doors to close copies of these products. These …

Under the umbrella of clinical pharmacology: inflammatory bowel disease, infliximab and adalimumab, and a bridge to an era of biosimilars

Z Petric, J Goncalves, P Paixao - Pharmaceutics, 2022 - mdpi.com
Monoclonal antibodies (MAbs) have revolutionized the treatment of many chronic
inflammatory diseases, including inflammatory bowel disease (IBD). IBD is a term that …

Trade secrets in biologic medicine: the boundary with patents

R Feldman - Colum. Sci. & Tech. L. Rev., 2022 - HeinOnline
SCIENCE & TECHNOLOGY Page 1 Trade Secrets in Biologic Medicine THE COLUMBIA
SCIENCE & TECHNOLOGY LAW REVIEW VOLUME XXIV STLR.ORG FALL 2022 ARTICLE …

The patent option

D Gervais - NCJL & Tech., 2018 - HeinOnline
Daniel Gervais, PhD* There is a shift in the shape of intellectual property tools used to
strengthen and lengthen the right of p Page 1 NORTH CAROLINA JOURNAL OF LAW & …

Qualified Immunity, Sovereign Immunity, and Systemic Reform

KM Crocker - Duke LJ, 2021 - HeinOnline
Qualified immunity has become a central target of the movement for police reform and racial
justice since George Floyd's murder. And rightly so. Qualified immunity, which shields …

[图书][B] That high design of purest gold: A Critical History of the Pharmaceutical Industry 1880–2020

G Dutfield - 2020 - World Scientific
This book is about medicines and the commercial actors that make and sell them. On the
face of it, it's hard to think of anything nobler than to bring to the world a medicine that saves …

International Regulatory Processes and Policies for Innovator Biologics, Biosimilars, and Biobetters

A Punia, H Malhotra - Biologics, Biosimilars, and biobetters: An …, 2020 - Wiley Online Library
Biologicals or biologics replicate endogenous substances such as enzymes, hormones, or
antibodies. They are derived from living cells or tissues of human, animal, and/or bacterial or …

[PDF][PDF] THE CAR-T CELL THERAPY INNOVATION DRIVERS: A YESCARTA CASE STUDY.

CR O'Brien Laramy - Berkeley Technology Law Journal, 2024 - btlj.org
A highly effective treatment for cancer lies within our own bodies: our immune system.
Chimeric antigen receptor (CAR)-T cell therapy harnesses patients' own immune cells to …

How non-product-specific manufacturing patents block biosimilars

C Song - Duke LJ, 2021 - HeinOnline
ABSTRACT A new class of drugs called biologics has potential to finally cure previously
untreatable conditions such as cancer and Alzheimer's disease. But there is a catch: these …